Typically, manuals of pediatric hematology-oncology are written by specialists from high-income countries, and usually target an audience with a sub-specialist level of training, often assisted by cutting-edge diagnostic and treatment facilities. However, approximately 80% of new cases of cancer in children appear in mid- and low-income countries. Almost invariably, general practitioners or general pediatricians without special training in oncology will look after children with malignancies who enter the health care system in these countries. The diagnostic facilities are usually limited, as are the treatment options. The survival figures in these conditions are somewhere below 20%, while in high-income countries they are in the range of 80% for many childhood cancers. Pediatric Hematology-Oncology in Countries with Limited Resources is the only book of its kind to provide specific guidance applicable to limited resource settings and builds up from the foundation of general practitioner or general pediatrician competence. Written and edited by leaders in the field, this manual educates physicians on the essential components of the discipline, filtered through the experience of specialists from developing countries, with immediate applicability in the specific healthcare environment in these countries.

2014 BMA Medical Book Awards Highly Commended in Internal Medicine category! This textbook on haematology in the Illustrated Colour Text series is suitable for medical students, junior doctors and others needing a concise and practical introduction to the subject. Concise and manageable coverage of the major blood diseases and their treatment. Does not overload the reader with science, unlike some competing books. Focus is on the haematology patient and on the practical aspects of the subject. Makes use of the attractive features of the ICT series - double page spreads, lots of colour illustrations, summary boxes. Updating to take account of recenty developments in stem cell biology. Increased emphasis on genomic and proteomic techniques in the diagnosis of haematological malignancy. Use of new imaging techniques including MRI and PET. Description of advances in treatment of leukaemia and lymphoma and in diagnosis and management of patients with thrombophilia and venous thrombosis. Development of new antimicrobial agents in management of immunosuppressed patients with infection. New double page spread on palliative care of patients with blood disorders. New illustrations.

This issue focuses on three disease sections: Diabetes, Hematology and Coagulation, and covers diagnostic and management issues during pregnancy of selected topics in each section. The chapters cover new concepts, evolving management and important impacts on the mother and unborn child.

This issue of Hematology/Oncology Clinics is edited by Dr. Jennifer Brown and focuses on Chronic Lymphocytic Leukemia. Article topics include: What Have Recent Genomic Advances Taught us About CLL?, Biology of CLL in Different Microenvironments, What is the Significance of Stereotyped BCRs in CLL?, Understanding Immunodeficiency in CLL, MBL vs CLL: How Important is the Distinction?, Risk Stratification of CLL in 2012, Minimal Residual Disease Measurement in CLL, The BTK Inhibitor PCI-32765 in CLL, and Evolving Role of Stem Cell Transplantation in CLL

This issue of Hematology/Oncology Clinics is guest edited by Dr. Christoph Klein and focuses on the topic of Neutropenia. Article titles include: Homeostasis and migration of neutrophil granulocytes, Granulocyte-colony Stimulating Factor (G-CSF) receptor signaling, New Granulocyte-colony Stimulating Factor (G-CSF) Receptor Signaling Pathways, Neutrophil elastase (ELANE) - Genetics and Pathophysiology, Autosomal recessive variants of Severe congenital neutropenia (SCN), Leukocyte Adhesion Deficiency (LAD), and Genotype-phenotype correlations in Severe congenital neutropenia (S

Topics include: Clinical Predictors of Outcome in MPNs; Molecular pathogenesis of MPNs; Disordered signaling in MPNs; Role of TET2/ASXL1 in MPN Pathogenesis; Pathogenesis and treatment of systemic mastocytosis; Role of additional novel therapies in MPNs; Role of novel mutations in MPN pathogenesis and outcome; Role of JAK inhibitors in MPN treatment; Animal Models of MPNs; and Role of Germline Genetic Factors in MPN Pathogenesis.

This invaluable book has been written specifically for trainee physicians preparing for the second part examination for membership of the Royal College of Physicians. It is in the format of this examination and the questions are typical of those used. The questions have been selected to cover sections of haematology which are particularly important for specialists in internal medicine. Although the questions have been formatted for this specific examination, the book will also be useful for those preparing for similar examinations in other countries and, in addition, will be helpful to those preparing for examinations of the Royal College of Pathologists. The text is well illustrated with clinical photographs and photomicrographs.The author has had many years' experience in the postgraduate education of trainee physicians, haematologists and pathologists, and has written several authoritative textbooks in the fields of haematology and haematopathology.

Topics include: A Critical re-appraisal of Factor VIIa; Thrombocytopenia: Hit vs non-HIT causes; Transfusion Reactions: Newer concepts on the pathophysiology, incidence, treatment and prevention of TRALI; The utility of diagnostic scoring systems for DIC; Newer anticoagulants; Anemia in the ICU; The role of plasmapheresis in critical illness; The use of erythropoiesis stimulating agents in the ICU; and Coagulopathy in the ICU: DIC vs Liver disease. Is this distinction important?

Topics in this issue?include: Targeting IGF-1R; Tyrosine Kinase Inhibitors in Lung Cancer; Targeting mTOR; Targeting Hedgehog; Mitotic Inhibitors; Topoisomerase I Inhibitors; and New Strategies and Drugs Inhibiting Folate Pathways.

Topics in this issue?include: Why does my patient have leukocytosis?; Why Is My Patient Neutropenic?; Does My Patient with a Serum Monoclonal Spike have Multiple Myeloma?; DVT and Pulmonary Embolism; Why Does My Patient Have Lymphadenopathy/Splenomegaly?; and Why Does My Patient have Thrombocytopenia?

Dr. Talpaz has assembled top experts to write state-of-the art reviews on the management of chronic myelogenous leukemia. Some of the articles that will be of most interest include Selection of Therapy: Rational Decisions Based on Molecular Events; Is There a Potential Cure for CML in Current Therapies?; Hurdles Toward a Cure for CML: The CML Stem Cell; The CML Stem Cell in the Chronic and Advanced Disease; CML Disease Progression; Management of Ph+ ALL and CML Blast Crisis; BMT in CML in the Era of Targeted Therapy; Pharmacoeconomics: The Cost of Staying Alive; and The Significance of CML Prognostic Factors in the Era of Targeted Therapy.

Topics for this issue will include: CLL: ? A Historical Perspective; Incidence & Epidemiology; Biology, Molecular Biology & Cytogenetics of CLL; What does the status of smatic hypermutations in IGVH genes tell us about the origin of CLL?; What does the status of ZAP-70 tell us about the biology of CLL?; and Approach to initial therapy: When to start therapy?

Topics?in this issue?include: Genetic Risk and Gynecologic Cancer; Current Management of Preinvasive Cervical Neoplasia; Current Surgical Management of Cervical Neoplasia; Current Surgical Management of Ovarian Cancer; Current Management of Trophoblastic Disease; and New Developments in Radiation Management and Gynecologic Cancers.

Thalassemia is discussed comprehensively by the authors in this issue.? Topics discussed include the population genetics and dynamimcs of thalassemia, alpha thalassemia, HbE/beta thalassemia, management of iron overload in thalassemia syndromes, allogeneic cellular gene therapy for hemoglobinopathies, cord blood transplantation for beta thalassemia major, and gene therapy for hemoglobin disorders.

The understanding of hemostasis physiology has been considerably advanced by models of kinetics and by the complicated interplay of cells and soluble coagulation factors. How this physiology is currently, or will eventually, be reflected in clinical laboratory testing is the subject of this monograph; this information is key for laboratorians to implement physiologic concepts into practical data and for clinicians to understand the basis of and therefore correctly treat hemostatic disease. Many thousands of patients present with bleeding disorders or bleeding complications of other diseases, and millions of individuals suffer the morbidity and mortality of thromboembolic complications. How laboratory testing confronts the challenge of predicting different hemostatic risks and guiding therapy is the critical subtext of the chapters in this monograph. New developments in hemostasis physiology have identified thrombin as an important, if not central, coordinator of hemostatic function and thus a target for measurement to assess hemostatic function and risk. Whether such measurements as endogenous thrombin potential or thromboelastography will accurately predict and/or quantitate global hemostatic function is an important question. Modeling the clinical risks of bleeding or thromboembolism currently uses the laboratory presence or absence of particular risk factors, but our clinical understanding of risk appears to more closely approximate a dynamic model, even within individual patients. Therefore, testing for platelet dysfunction or comprehending the functional implications of a lupus anticoagulant may rely on our evolving comprehension of hemostasis phyisology and perhaps require more sophisticated interpretation of clinical predictors of hemostatic risk. This monograph aims to shed some light in these areas and promote investigation of such key hemostasis issues.

This book highlights the importance of the choroid plexus, which forms the blood-cerebrospinal fluid barrier and is the site of the major production of the cerebrospinal fluid (CSF). The authors show that this barrier is crucial for maintaining important compositional differences between the blood plasma and the CSF. The choroid plexus epithelial cells also prevent the spread of infectious agents and other blood-borne entities to the brain tissue. Chapter topics range from the production of CSF by electrolyte regulation in the choroid plexus, to details on the selectively transporting nature of this barrier. Further, the authors elaborate on the important roles of CSF in sustaining brain health by providing hydration, solutes, and nutrients to the brain tissue. Readers will also learn how CSF circulates signaling molecules within the compartments of the brain and removes waste products from the brain tissue. Elucidating the regulation of these processes in the choroid plexus is not only important for the readers' understanding of normal brain development and function, but is also crucial for resolving a variety of cerebral challenges that lead to brain edema, as well as developing treatments for diseases. The book discusses disease models like hydrocephalus, sleep disorders, and age-related dementia. Its comprehensive coverage makes this volume a valuable resource for researchers in cell and neurophysiology, as well as graduate students of the neurosciences.

Managing infections that complicate care of neutropenic patients with leukemia and hematopoietic stem cell recipients has become a distinct specialty. In Managing Infections in Patients with Hematological Malignancies, the authors and editor draw on their extensive expertise while providing a roadmap for hematologists to efficiently manage the complex infections within their patients. The first section of the text reviews viral, bacterial, and fungal pathogens, and provides brief descriptions of the microbes and diseases they cause in patients with hematological malignancies. The second section is devoted to management of infections in patients with the different underlying hematological malignancies, while the third addresses several important topics that are often ignored in most books about infections and hematological malignancies. Managing Infections in Hematological Malignancies is a useful tool for all clinicians and practicing hematologists who treat individual patients and aspire to build stronger infectious diseases programs within their respective cancer centers.

Many diseases earlier considered to be incurable are now being treated with modern innovations involving fetal tissue transplants and stem cells derived from fetal tissues. Fetal tissues are the richest source of fetal stem cells as well as other varying states of differentiated cells and support or stromal cells. The activity of such stem cells is at their peak provided they are given the correct niche. Stem cells, as we know, are immortal cells with the capacity to regenerate into any kind of differentiated cell as per niche-guidance. As such, fetal tissues have the potential capacity to mend, regenerate and repair damaged cells or tissues in adults, when directly transplanted to the site of injury, or even when transplanted in some other site, because it may have a homing capacity to migrate to the site of the specific injured organ. This is a new area of translational research and needs to be highlighted because of its immense potential. This book will bring together the new work of prominent medical scientists and clinicians who are conducting pioneering research in human fetal tissue transplantation. This will include direct transplant of healthy fetal tissue into mature patients as well as in hosts with genetic diseases. Transplant techniques, donor-host interaction, cell and tissue storage, ethical and legal issues, are some of the many matters which the book will deal with.

The mature T and NK cell lymphomas are rare, comprising approximately 10% of all malignant lymphomas. The incidence of T- cell lymphoma is variable around the world, with a higher incidence compared to B-cell lymphomas in the Asian basin. While the overall incidence of B-cell lymphomas has begun to decline in the United States, the incidence of T-cell lymphomas continues to rise. Over the last decade, a number of novel agents have been developed which target T-cell lymphomas and studies have identified novel genes and pathways associated with lymphomagenesis in T-cells. This comprehensive volume examines the clinical and biological aspects of the T-cell lymphoproliferative disorders in adults and children. The book includes an overview of both the cutaneous and the systemic T-cell malignancies and addresses the classification of T-cell lymphomas, the clinical features of each subtype, and the relevant molecular and genetic studies. Clinical outcomes and treatment strategies are discussed with an emphasis on the development of novel biological and targeted therapies. An outstanding resource for hematologists and oncologists, this book gathers insights from experts in the field and provides the most up-to-date information on all of the T-cell lymphoma subgroups and current and emerging therapies.

This book provides a concise set of protocols for assessing basic neutrophil functions, investigating specialized areas in neutrophil research, and completing step-by-step diagnostic assays of common neutrophil disorders. Each of the protocols is written by leading researchers in the field and includes hints for success, as well as guidance for troubleshooting. Scientists and clinicians will find this collection an invaluable aid.